Skip to content
Search

Latest Stories

Community pharmacies in seven PCNs selected to join NHS contraception management service pilot

A number of community pharmacies in England have been chosen to offer contraceptive pill checks as part of a pilot scheme from NHS England.

The tier 1 pilot aims to test a "model for community pharmacy teams to continue the supply and management" of NHS patients taking oral contraception.


It is hoped that the service will create more capacity in primary care and sexual health clinics and improve access for patients but it is not a replacement for local authority commissioned services.

The objectives of the pilotare to:

  • test a model for community pharmacy teams to continue, review and supply the provision of contraception supplies initiated in primary care or sexual health clinics
  • test an integrated pathway between existing services and community pharmacies to allow people greater choice and access when considering continuing their current form of contraception
  • create better access to services and support for high-risk communities and vulnerable patients
  • identify a data set that should be shared with the community pharmacy to support the referral process and feedback loop to the GP-held patient record where appropriate (with relevant consent)
  • evaluate the tier 1 service model exploring the experience of service users, pharmacy staff and primary care and sexual health professionals and the preferred care model of the service within community pharmacy

RPS welcomes contraceptive pilot

“We are pleased that the pilot will improve access to contraception and sexual health services and, as medicines experts, pharmacists are well placed to deliver this service and support the public with healthcare advice, said Thorrun Govind, chair of the Royal Pharmaceutical Society English Pharmacy Board.

“People seeking this support for contraception can be assured that pharmacists are trained to deliver contraceptive services, as seen recently with the move to offer a progestogen-only pill over the counter at pharmacies.

“The public will be able to visit a pharmacy without an appointment and receive support and advice from a trained professional, whilst also reducing pressure on general practice and the NHS.”

The scheme started on Thursday, September 30 and will run for a year with the possibility of extension.

Currently it is being piloted in selected primary care networks (PCNs) in South Yorkshire and Bassetlaw; NE Lincolnshire; Hull CCGs within Humber, Coast and Vale; Cumbria and NE; Lancashire and South Cumbria; Suffolk and NE Essex ICS; and Staffordshire.

Contractors eligible to take part in this pilot will be contacted by their NHS England and NHS Improvement regional team.

Payment for provision

Reimbursement will be paid on the condition that the participating pharmacy has provided the service in accordance with the service specification. The pilot will pay £18.50 per consultation and each participating pharmacy will be paid a one-off sum of £685 to meet the set-up costs for the service.

Pharmacists who take part in an evaluation interview can claim a separate one-off payment of £125 per pharmacy.

Additionally, a participating pharmacy contractor can claim a one-off payment of £550 if they make a declaration that they have participated in the evaluation and data submission and will keep records to evidence the declaration.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less